Reactive infectious mucocutaneous eruption secondary to SARS‐CoV‐2 and influenza A coinfection with varicella zoster virus reactivation

Reactive infectious mucocutaneous eruption (RIME) is a newly proposed clinical entity characterised by post‐infectious mucositis involving two or more mucous membranes. The term expands the previously described Mycoplasma pneumoniae‐induced rash and mucositis to include additional infectious agents....

Full description

Saved in:
Bibliographic Details
Published in:JEADV clinical practice 2023-09, Vol.2 (3), p.617-620
Main Authors: Moshayedi, Aref, Malachowski, Stephen J., Haught, Justin
Format: Article
Language:English
Subjects:
Bacterial infections
Chicken pox
Conflicts of interest
COVID‐19
Dermatology
Editing
Emergency medical care
Infections
Influenza
Information sharing
Mucositis
Otolaryngology
Patients
Pediatrics
RIME
SARS‐CoV2
Severe acute respiratory syndrome coronavirus 2
SJS
TEN
Viral infections
Viruses
VZV
Writing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reactive infectious mucocutaneous eruption (RIME) is a newly proposed clinical entity characterised by post‐infectious mucositis involving two or more mucous membranes. The term expands the previously described Mycoplasma pneumoniae‐induced rash and mucositis to include additional infectious agents. We report a case of RIME secondary to SARS‐CoV2 and Influenza A coinfection with subsequent reactivation of varicella zoster virus on the lips. RIME can have significant clinical overlap with Stevens‐Johnson Syndrome and differentiation is key in limiting unnecessary future medication restrictions on patients. This report serves to increase awareness of RIME, including to coinfections and possible reactivation of Human Herpes Viruses.
ISSN:2768-6566
2768-6566
DOI:10.1002/jvc2.172